Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.

Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH.

Blood. 2010 Dec 23;116(26):5824-31. doi: 10.1182/blood-2010-04-282392. Epub 2010 Sep 20.

2.

Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis.

Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C, Davies G, Webb D, Veys P, Amrolia P.

Blood. 2006 Feb 1;107(3):1233-6. Epub 2005 Oct 11.

3.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)..

Haematologica. 2007 May;92(5):627-34.

4.

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10.

5.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10.

7.

Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.

Hamidieh AA, Pourpak Z, Hashemi S, Yari K, Fazlollahi MR, Movahedi M, Behfar M, Moin M, Ghavamzadeh A.

Eur J Haematol. 2014 Apr;92(4):331-6. doi: 10.1111/ejh.12244. Epub 2014 Jan 10.

PMID:
24330187
8.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
9.

Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.

Gonzalez-Llano O, Jaime-Pérez J, Cantu-Rodríguez O, Mancias-Guerra C, Gutierrez-Aguirre H, Herrera-Garza J, Gomez-Almaguer D.

Eur J Haematol. 2006 Oct;77(4):341-4. Epub 2006 Jul 19.

PMID:
16856932
10.

Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.

Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.

Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9.

PMID:
12652466
11.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

12.

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.

J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.

PMID:
26424692
13.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.

Bone Marrow Transplant. 2000 Oct;26(7):711-6.

14.

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.

Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003. Epub 2014 Jun 9.

15.

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.

Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.

Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83.

16.

Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.

Lehmberg K, Albert MH, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I.

Haematologica. 2014 Jan;99(1):180-4. doi: 10.3324/haematol.2013.094730. Epub 2013 Oct 25.

17.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.

PMID:
17869547
18.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group..

Ann Hematol. 2003 Jun;82(6):336-42. Epub 2003 May 1.

PMID:
12728337
19.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.

Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT)..

Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006. Epub 2010 Apr 24.

20.

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE.

Blood. 2003 Nov 15;102(10):3829-36. Epub 2003 Jul 24.

Supplemental Content

Support Center